Sign in
Not yet taking people in United StatesNo phase

Cognitive Augmentation, Remediation, and TDCS for Schizophrenia

Key facts

Who runs it
Beth Israel Deaconess Medical Center
Where
Boston, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
10 people, planned
Starts
Dec 2026
Expected to end
Nov 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High-definition transcranial direct current stimulation
  • Cognitive remediation therapy
  • Sham cognitive remediation therapy
Record updated
17 November 2026

Who can take part

Age
18 years to 40 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • Proficient in English
  • IQ >= 80

Who cannot take part

  • Changes to relevant medications within 1 month of enrollment
  • Positive urine drug screen for illicit substances
  • Major neurological conditions
  • Moderate to severe DSM V substance use disorder
  • Skin allergy to lidocaine or electrolyte gel
  • Implanted devices in the body or metal in the head
  • Pregnancy or breastfeeding
  • Clinical instability including recent or severe suicidal ideation or actions

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Rebekah L Trotti, PhDNot yet recruiting

About the trial

What the trial wants to find out

Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.

Read full original descriptionShow less

This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.

The 2 groups in the trial

  • NIBS+Treatment being tested

    Combined transcranial direct current stimulation and cognitive remediation therapy (both active)

    Treatment: High-definition transcranial direct current stimulation and Cognitive remediation therapy

  • NIBS-Existing treatment, for comparison

    Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT)

    Treatment: High-definition transcranial direct current stimulation and Sham cognitive remediation therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Criteria questions
Built from NCT07940712, who can take part
Record updated
17 November 2026